ANDREA SLOAN, an ovarian cancer patient whose efforts to get access to a BioMarin drug attracted national media attention, died from complications of pneumonia Jan. 1 (The Cancer Letter, Nov. 8, 2013). Sloan, an Austin attorney, was 45.
Andrea Sloan, Prominent Ovarian Cancer Patient Dies
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.


Cancer care is evolving at an unprecedented pace. Practitioners feel the mounting pressures daily: rising cancer rates—particularly in younger patients—a growing population of older cancer survivors, rapid growth in new care and treatment options, and navigating heightened fiscal constraints and uncertainty.


In 1988, Frank McCormick learned with the rest of the field that more than 90% of patients with pancreatic cancer have a mutation in the Kirsten rat sarcoma viral gene.


As every non-profit organization knows, it is our obligation to be purpose-driven. Most NPO founders and the people who work for them have been thrown into this space as a result of life experiences. It is our passion rather than a job to simply collect a paycheck.


A report by the American Society of Clinical Oncology points to a growing challenge in cancer care access driven by a widening gap between the number of available oncologists and increasing patient demand.

